Fairbanks Presents at MassCONNECT Final Showcase

May 23, 2017Company NewsMassCONNECtMark Schneyer

Fairbanks Pharmaceuticals presented its unique and innovative approach to attacking the underlying pathology of diabetes by increasing insulin production from existing beta cells and simultaneously inducing regeneration of beta cells at the MassCONNECT Final Showcase on May 18^th 2017. The presentation was met with widespread interest from both pharma and private investors.

The Final Showcase was the culmination of an eight-week mentorship program with a team of biotech and pharmaceutical industry leaders to help with strategic planning, identifying potential partners and financing, and developing a slide deck.

Fairbanks Supports March for Science and Biomedical Research

April 27, 2017Company NewsBiomedical ResearchMark Schneyer

Fairbanks co-founder Alan Schneyer joined thousands of demonstrators on Boston Common to support biomedical research as part of the March for Science on April 21.

In this picture, featured in the Boston Globe, Alan sports a sign about the benefits of scientific research.

MTTC Early-Stage Life Sciences Technology Conference

March 3, 2017Company NewsElissa Brown

Fairbanks was selected to present at UMass’ Technology Transfer Center’s Early-Stage Life Sciences Technology Conference on April 5, 2017. The presentation will focus on our technology, IP, potential markets, sustainable competitive advantage, developmental stage, and future plans. Stay tuned for a release of our latest slide deck.

MassBio Council MassConnect Program

March 1, 2017Company NewsMaBio, MassCONNECtElissa Brown

Fairbanks CEO Alan Schneyer presenting at MassConnect — Fairbanks CEO Alan Schneyer presenting

Alan Schneyer and Elissa Brown gave Fairbanks’ introductory pitch today to MassBio’s 2017 Cycle 1 MassConnect mentors. Fairbanks was one of four biotech startups selected by MassBio to join the only entrepreneur mentorship program in Massachusetts that dives deep into the life sciences. MassCONNECT matches entrepreneurs and founders with seasoned life sciences professionals to catalyze and commercialize innovation.

The MassCONNECT process involves a two-month mentorship where industry experts guide entrepreneurs as they seek to develop business plans, launch companies, and raise capital.
MassCONNECT mentors evaluate and provide feedback on commercial feasibility; identify strengths, weaknesses, opportunities and threats; and team up to furnish industry-specific business advice for innovative ideas in therapeutics, diagnostics, medical devices and health IT. Entrepreneurs gain invaluable advice and coaching on defining value proposition, developing pitches and building professional networks.

Click here for more information on today’s kick-off.

Alan Schneyer (6th from right) and Elissa Brown (3rd from right) with other MassConnect participants

Boehringer-Ingelheim Boston Innovation Prize

February 12, 2017Company NewsElissa Brown

(December 2016) Boehringer-Ingelheim Pharmaceuticals (BI) selected Fairbanks from 30 applicants to compete for their Boston Innovation Prize. BI runs this competition to help sustain innovative pipelines for new breakthrough therapies by providing a Golden Ticket for Lab Central space (valued at $75,000) in Cambridge, MA. The panel of judges includes senior and founding members of Lab Central and BI’s venture capital fund, as well as other seed stage investor groups.

We’re growing!

September 30, 2016Company NewsMark Schneyer

We’re growing! Fairbanks Pharmaceuticals is now Fairbanks Pharmaceuticals, Inc., incorporated in the state of Delaware and registered in the Commonwealth of Massachusetts.

Fairbanks Pharmaceuticals awarded UMass pilot grant

September 30, 2016AwardsMark Schneyer

Fairbanks Pharmaceuticals was awarded a pilot grant from the UMass Office of the President’s Science and Technology Fund to screen small molecules with the goal of identifying compounds that will promote the transdifferentiation of pancreatic alpha cells into insulin secreting beta cells.

This highly competitive funding program was created by UMass to stimulate the development of high impact therapeutic candidates. Proposals were selected based on assay feasibility, medical relevance, and commercialization potential.

Fairbanks Pharmaceuticals to compete in semifinals of Diabetes Innovation Challenge

September 12, 2016Company NewsAlan Schneyer

Fairbanks Pharmaceuticals has been selected as a semi-finalist in the Diabetes Innovation Challenge sponsored by the T1D Exchange, the Massachusetts Medical Device Development Center (M2D2) at UMass, the Juvenile Diabetes Research Foundation (JDRF) and the American Diabetes Association (ADA).

The Challenge is a proposal- and presentation-based competition for small companies in the T1 and T2 space that are making real progress towards better outcomes for those diagnosed. It offers the chance to win in-kind awards and receive early and later-stage validation of their ideas and products specific to Type 1 and Type 2 diabetes.

Read more about the Challenge, or come see us at UMass Lowell on October 5th, 2016 at the pre-clinical “pitch-off.”

Fairbanks Pharmaceuticals Awarded second MLSC Intern

August 10, 2016AwardsMark Schneyer

Fairbanks Pharmaceuticals received a second award from the Massachusetts Life Science Center to hire a new technician intern starting in July 2016. Alyssa Berthelette, a 2016 graduate from Assumption College with a degree in Biology, was selected to replace Eddie Mesiti who departed July 31 to continue his education. Welcome Aboard Alyssa!

Fairbanks Pharmaceuticals awarded a Phase 1 SBIR grant for $192,101 by NIDDK/NIH

April 13, 2016Awards, Company NewsMark Schneyer

Dr. Alan Schneyer, CEO/CSO and Co-founder of Fairbanks Pharmaceuticals, is the Principal Investigator (PI) of an SBIR grant from The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at The National Institutes of Health (NIH). The award begins immediately and funds our research that will identify a number of candidate compounds using our proprietary screening bioassay, comparing them for biochemical and biological properties, and testing the top candidates for biological activity in islet culture assays.

The award lasts for a one year period. It is anticipated that the successful completion of this Phase 1 award will lead to a larger Phase 2 award, which will allow testing the biological activity of lead compounds in animals. The goal of Fairbanks Pharmaceuticals, and this SBIR grant, is to develop compounds that lead to regeneration of insulin-producing beta cells to replace those lost to either type 1 or type 2 diabetes and thereby partially or completely eliminate diabetes in these patients. Stay tuned for progress reports….